Intec Pharma Ltd. | Income Statement

Fiscal year is January-December. All values ILS Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
2,176.00
2,092.00
2,898.00
2,691.00
2,981.90
859
Gross Income
2,176.00
2,092.00
2,898.00
2,691.00
2,981.90
859
SG&A Expense
16,474.00
24,980.00
26,631.00
50,460.60
102,909.40
42,469
EBIT
18,650.00
27,072.00
29,529.00
53,151.60
105,891.30
43,328
Unusual Expense
506.00
107.00
753.00
1,013.40
129.50
194
Non Operating Income/Expense
648.00
5,980.00
2,224.00
230.30
251.80
747
Interest Expense
-
-
-
61.40
61.10
23
Pretax Income
18,390.00
20,368.00
27,884.00
51,293.60
104,542.50
43,440
Income Tax
-
-
-
-
104.30
103
Consolidated Net Income
18,390.00
20,368.00
27,884.00
51,293.60
104,646.80
43,543
Net Income
18,390.00
20,368.00
27,884.00
51,293.60
104,646.80
43,543
Net Income After Extraordinaries
18,390.00
20,368.00
27,884.00
51,293.60
104,646.80
43,543
Net Income Available to Common
18,390.00
20,368.00
27,884.00
51,293.60
104,646.80
43,543
EPS (Basic)
4.50
4.00
3.58
4.49
5.93
1.40
Basic Shares Outstanding
4,287.60
4,825.00
7,791.00
11,448.00
17,660.00
31,193
EPS (Diluted)
4.29
4.22
3.58
4.48
5.93
1.40
Diluted Shares Outstanding
4,287.60
4,825.00
7,791.00
11,448.00
17,660.00
31,193
EBITDA
16,474.00
24,980.00
26,631.00
50,460.60
102,909.40
42,469
Non-Operating Interest Income
402.00
617.00
174.00
675.60
1,028.70
852

About Intec Pharma

View Profile
Address
RMPE Building
Jerusalem JM 9777512
Israel
Employees -
Website http://www.intecpharma.com
Updated 07/08/2019
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which focuses on developing drugs based on its proprietary Accordion Pill platform technology. Its product pipeline includes four product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients; Accordion Pill Zaleplon, which is being developed for the treatment of insomnia, including sleep induction and the improvement of sleep maintenance; an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug which induces ulcers; and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol and tetrahydrocannabinol, which is being developed for various indications including low back neuropathic pain and fibromyalgia. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.